SecBot SecBot
Biotech Drug Report Generated Aug 1, 2026

CINGAL

ANIK·Anika Therapeutics, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Pre-NDA (US drug application path; not a standard clinical phase)
Time to market
Unknown, and likely 2027 at the earliest: the NDA had not been confirmed as filed as of mid-2026, and a US approval decision would typically come roughly 10 months after a completed, accepted submission.
Why 3/10
No hard, dated catalyst is scheduled for Cingal in the next ~12 months: the NDA submission expected around Dec 31, 2025 (per the Nov 2025 10-Q) was still an open "timeline to monitor" as of the July 29, 2026 earnings update, and no PDUFA date exists in the data, a pre-NDA program that is one of several assets (Monovisc, Orthovisc, Hyalofast, Integrity) at a ~$200M company scores 3.
Actionable Insight NEUTRAL

Watch Anika's Q3 2026 earnings call (next scheduled update) for a confirmation that the Cingal NDA was formally submitted and for FDA acceptance, that would finally give the stock a dated regulatory clock. Until a submission is confirmed, treat Cingal as a 2027+ US revenue story, not a near-term binary; near-term price action is being driven by the Q2 2026 earnings beat and guidance raise rather than by Cingal news.

Price Chart

Loading chart...

Executive Summary

Cingal is Anika Therapeutics' (Nasdaq: ANIK, ~$19.28/share, ~$202M market cap) osteoarthritis pain-management product candidate heading to the US market via an NDA that requires two studies including a bioequivalence study; the NDA submission was expected around end-2025 per the Nov 2025 10-Q but remains an unconfirmed, unscheduled item as of the Q2 2026 earnings update. Cingal is one of five named products in Anika's portfolio (with Monovisc, Orthovisc, Hyalofast, Integrity), so the company's value does not ride on it alone.

How It Works

Cingal is Anika's single-injection product for osteoarthritis pain management. Under the US regulatory path described in the company's filings, it is being developed as a drug through an FDA NDA that requires completion of two studies including a bioequivalence study, a route that compares the product's absorption/profile against a reference rather than running a full-scale Phase 3-style efficacy program.

Trial Status

Per the Nov 5, 2025 10-Q (SEC catalyst record), the FDA's NDA path for Cingal requires completion of two studies, with bioequivalence study initiation on track for before year-end 2025; the NDA submission was expected around Dec 31, 2025 but no submission/acceptance was confirmed in the July 2026 earnings materials, and the stock showed essentially no reaction (+0.63% 1-day, -0.84% 5-day) around that expected submission date.

The Two-Sided Case

▲ Bull Case4
Clear regulatory route: the FDA has defined an NDA path requiring two studies including a bioequivalence study, with initiation on track for before year-end 2025 per the Nov 5, 2025 10-Q, a defined path rather than an open-ended clinical program.
US launch would be a new revenue stream: Anika's commercial channel is already firing, record Commercial Channel revenue of $13.9M (+17% YoY) in Q2 2026, the same sales infrastructure a Cingal US approval would plug into.
Wall Street is constructive on the stock: analyst consensus shows 7 of 8 ratings at Buy/Strong Buy (4 buy, 3 strong buy, 1 hold), mean price target of $21 (vs ~$19.28 current price), and B. Riley maintained Buy after the Q2 2026 beat.
Management skin in the game: CEO and a director bought $223K of open-market shares in the week after Q1 2026 earnings (May 2026 insider cluster).
▼ Bear Case5
Timeline slippage: the NDA submission expected around Dec 31, 2025 (per the Nov 2025 10-Q) was still an open 'Cingal NDA timeline to monitor' as of the July 29, 2026 earnings report, no submission or FDA acceptance had been confirmed, and no PDUFA date exists in the data.
No dated catalyst: with the next hard regulatory event unscheduled, there is no binary to trade; the stock moved only +0.63% (1-day) around the expected NDA-submission date, suggesting limited near-term price sensitivity to Cingal progress.
FDA-timing precedent at the company: sibling product Hyalofast received an FDA deficiency letter and was removed from 2027 revenue guidance due to FDA timing uncertainty, evidence that this FDA pathway can slip.
Balance-sheet constraints: cash fell to $38.4M at June 30, 2026 from $57.5M at Dec 2025 (share repurchases and inventory build), with negative YTD operating cash flow (-$5.5M), limiting flexibility to fund a slow regulatory slog.
Competitive market context: Anika itself already sells multiple knee OA injections (Monovisc, Orthovisc), and Cingal will enter a crowded osteoarthritis injection category with no demonstrated US commercial traction yet.

Upcoming Catalysts

  • Confirmation of Cingal NDA submission + FDA acceptance (timing unscheduled, the key thing to watch on the Q3 2026 earnings call)
  • Q3 2026 earnings call (next scheduled update) for Cingal NDA timeline guidance
  • Hyalofast PMA FDA decision, related pipeline overhang that management removed from 2027 guidance
  • Ongoing commercial-channel revenue momentum from Monovisc/Orthovisc and international sales

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Anika Therapeutics, Inc. 8-K ANIK ·Originating report

Sources · 6

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 globenewswire.com5 globenewswire.com6 globenewswire.com